Xin Liu

Xin Liu


Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
6 July 2023 in Frontiers in Oncology
Verified
Journal Article
Open access
MBMaoshu Bai
Maoshu Bai
XLXin Liu
Xin Liu
Kinesin family member 23 (KIF23), an index of tumor proliferation, can serve as a prognostic marker in numerous tumors. However, the relationship between KIF23 expression and diagnostic value, immune infiltration, and immunotherapy response remains unclear in gastric cancer(GC). We primarily demonstrated that GC tissue had higher levels of KIF23 expression than the adjacent normal tissue on mRNA and protein levels. The ROC analysis revealed KIF23 had an outstanding diagnostic value of GC in the training and validation set (AUC = 0.958, and AUC = 0.86793, respectively). We discovered that KIF23 was positively associated with age, histological type, and H. pylori infection of GC. Subsequently, the KIF23 expression level was correlated with the gene mutation, function enrichment, immune cell infiltration, and immune cell marker of GC based on multiple online websites and R software. KIF23 expression was related to the infiltration of CD8+ T cells, CD4+T cells, macrophages, and dendritic cells in GC. Especially, KIF23 expression was positively significantly associated with the Th1 cell marker STAT1 (Signal transducer and activator of transcription 1). Patients with high KIF23 expression exhibited greater immune cell infiltrates, including T cell CD4+ memory helper, Treg, and M1 cells, which indicated that high KIF23 expression is more conducive to immunosuppression. Finally, KIF23 expression had a positive relationship with TMB and MSI, and affected the immune microenvironment in GC tissues by increased expression of ICPs such as CD274(PD-L1), CTLA4, HAVCR2, and LAG3. Our study uncovered that KIF23 can serve as an immune-related biomarker for diagnosis and immunotherapy response of GC.

21 February 2023 in Medical Oncology
Verified
Journal Article
Closed access
PDF file
MBMaoshu Bai
Maoshu Bai
XLXin Liu
Xin Liu
LWLingling Wang
Lingling Wang

11 January 2022 in Research Square
Verified
Preprint
Open access
PDF file
MBMaoshu Bai
Maoshu Bai
XLXin Liu
Xin Liu
BackgroundKinesin family member 23 (KIF23), an index of tumor proliferation, can serve as a prognostic marker in numerous tumors. However, the relationship between KIF23 expression and immune infiltration and the diagnostic value of KIF23 remain unclear in GC (gastric cancer). This study aimed to explored the prognosis value of KIF23 and its interactions with tumor-infiltrating immune cells in GC by bioinformatics analysis. ResultsThe relationship between clinicopathologic features and KIF23 expression was also analyzed using the Wilcoxon rank-sum test and logistic regression. And the expression level of KIF23 was validated by IHC and GEO databases, which was consistent with informatics results. Receiver operating characteristic (ROC) curves were generated to evaluate the value of KIF23 as a binary classifier using the area under the curve (AUC value). High expression of KIF23 was significantly associated with longer overall survival and progression-free survival in GC. The mutations of KIF23 in GC were analyzed using cBioPortal and the Catalogue of Somatic Mutations in Cancer database. Enrichment analysis of co-expressed genes and KIF23 analysis was performed using LinkedOmics. By using STRING and GeneMANIA databases, we investigated the protein-coding genes related to KIF23 and its co-expression genes in GC tissues. Then, the relationship between KIF23 expression and immune infiltration in GC was investigated using Timer and GEPIA. We found that KIF23 might be used as a potential prognosis biomarker in GC. Subsequently, KIF23 expression level was correlated with the infiltration levels of CD8 + T cells, macrophages, neutrophils, and more obviously with B cells and dendritic cells. In addition, KIF23 expression was significantly associated with T cell exhaustion (CTLA-4 and GZMB). KIF23 expression showed correlations with the infiltration of diverse immune markers in GC. ConclusionOur findings suggest KIF23 can serve as a marker for immune infiltration and prognosis in GC.

18 August 2026 in Molecular Biology Reports
Verified
Journal Article
Closed access
LTLinghan Tian
Linghan Tian
YWYuanbiao Wang
Yuanbiao Wang
LHLi Huang
Li Huang
YMYuanyuan Meng
Yuanyuan Meng
WWWei Wu
Wei Wu
XLXin Liu
Xin Liu

5 November 2026 in Frontiers in Oncology
Verified
Journal Article
Open access
PDF file
ZLZhuoying Li
Zhuoying Li
RLRui Liu
Rui Liu
JWJianping Wu
Jianping Wu
HLHaozhe Li
Haozhe Li
XWXiaoxiong Wang
Xiaoxiong Wang
YZYongchun Zhou
Yongchun Zhou
Epidermal growth factor receptor (EGFR) gene mutation stands as one of the most prevalent driver genetic alterations in non-small cell lung cancer (NSCLC). While targeted therapies against EGFR have substantially enhanced patient prognosis, acquired resistance remains a core challenge that limits therapeutic efficacy. Patients with stage IV NSCLC generally exhibit a dismal prognosis, with only about 7% of those with stage IVB disease surviving beyond five years. Herein, we report a case of a 47-year-old female patient diagnosed with advanced lung adenocarcinoma, whose clinical course has persisted for nearly a decade. Initial genetic testing identified an EGFR exon 19 deletion (19del). Following treatment with osimertinib, the patient developed concurrent cis-arranged EGFR T790M/C797S double mutations and a neurotrophic receptor tyrosine kinase 1 (NTRK1) gene rearrangement. Subsequently, through a multimodal therapeutic strategy integrating local intervention, radiation therapy, and targeted therapy, the patient’s disease has been sustainably controlled for several years, and she remains alive with stable clinical status to date. NTRK1 fusions are a well-defined mechanism of acquired resistance to EGFR-TKIs, but they are uncommon. This case reports a KIF26B-NTRK1 rearrangement not previously described in lung cancer; however, its functional significance remains to be confirmed. The principal value of this report lies in the completeness of the longitudinal molecular and clinical record, which documents how an on-target mutation and a bypass rearrangement can coexist and persist.